JP2024509269A - 脳がんの治療における使用のためのベルバラフェニブ - Google Patents

脳がんの治療における使用のためのベルバラフェニブ Download PDF

Info

Publication number
JP2024509269A
JP2024509269A JP2023555290A JP2023555290A JP2024509269A JP 2024509269 A JP2024509269 A JP 2024509269A JP 2023555290 A JP2023555290 A JP 2023555290A JP 2023555290 A JP2023555290 A JP 2023555290A JP 2024509269 A JP2024509269 A JP 2024509269A
Authority
JP
Japan
Prior art keywords
mutation
cancer
nras
melanoma
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509269A5 (https=
Inventor
ジョアン アダムケービッチ，
マイケル ジョン ドルトン，
シヴァ マレク，
ピーア トーマス，
ジェニファー オン－ウォン，
イビン ヤン，
ヨンフン キム，
ヨンギル アン，
ユヨン キム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of JP2024509269A publication Critical patent/JP2024509269A/ja
Publication of JP2024509269A5 publication Critical patent/JP2024509269A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023555290A 2021-03-09 2022-03-08 脳がんの治療における使用のためのベルバラフェニブ Pending JP2024509269A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163158798P 2021-03-09 2021-03-09
US63/158,798 2021-03-09
PCT/US2022/019273 WO2022192202A1 (en) 2021-03-09 2022-03-08 Belvarafenib for use in treatment of brain cancers

Publications (2)

Publication Number Publication Date
JP2024509269A true JP2024509269A (ja) 2024-02-29
JP2024509269A5 JP2024509269A5 (https=) 2025-03-17

Family

ID=80952247

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555290A Pending JP2024509269A (ja) 2021-03-09 2022-03-08 脳がんの治療における使用のためのベルバラフェニブ

Country Status (7)

Country Link
US (1) US20240173329A1 (https=)
EP (1) EP4304592A1 (https=)
JP (1) JP2024509269A (https=)
KR (1) KR20230156731A (https=)
CN (1) CN117940130A (https=)
TW (1) TW202300151A (https=)
WO (1) WO2022192202A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
JP2015503553A (ja) * 2011-12-30 2015-02-02 ハンミ ファーム． シーオー．， エルティーディー． プロテインキナーゼに対する阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
WO2020261156A1 (en) * 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
JP2021504437A (ja) * 2017-11-30 2021-02-15 ハンミ ファーム．カンパニー リミテッドＨａｎｍｉ Ｐｈａｒｍ．Ｃｏ．，Ｌｔｄ． ４−アミノ−ｎ−（１−（（３−クロロ−２−フルオロフェニル）アミノ）−６−メチルイソキノリン−５−イル）チエノ［３，２−ｄ］ピリミジン−７−カルボキサミドの塩とその結晶形態
JP2023531375A (ja) * 2020-05-26 2023-07-24 ハンミ ファーム．カンパニー リミテッド がん治療における使用のためのベルバラフェニブ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1934174T1 (sl) 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
KR20190057421A (ko) 2012-08-17 2019-05-28 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
KR102204520B1 (ko) 2012-10-12 2021-01-20 엑셀리시스, 인코포레이티드 암의 치료에 사용하기 위한 화합물의 신규 제조 방법
EP3624896A4 (en) * 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
EP3560516A1 (en) * 2018-04-27 2019-10-30 Bergen Teknologioverforing AS Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
JP2015503553A (ja) * 2011-12-30 2015-02-02 ハンミ ファーム． シーオー．， エルティーディー． プロテインキナーゼに対する阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
JP2021504437A (ja) * 2017-11-30 2021-02-15 ハンミ ファーム．カンパニー リミテッドＨａｎｍｉ Ｐｈａｒｍ．Ｃｏ．，Ｌｔｄ． ４−アミノ−ｎ−（１−（（３−クロロ−２−フルオロフェニル）アミノ）−６−メチルイソキノリン−５−イル）チエノ［３，２−ｄ］ピリミジン−７−カルボキサミドの塩とその結晶形態
WO2020261156A1 (en) * 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
JP2023531375A (ja) * 2020-05-26 2023-07-24 ハンミ ファーム．カンパニー リミテッド がん治療における使用のためのベルバラフェニブ

Also Published As

Publication number Publication date
KR20230156731A (ko) 2023-11-14
US20240173329A1 (en) 2024-05-30
WO2022192202A1 (en) 2022-09-15
CN117940130A (zh) 2024-04-26
EP4304592A1 (en) 2024-01-17
TW202300151A (zh) 2023-01-01

Similar Documents

Publication Publication Date Title
JP7520189B2 (ja) 組み合わせ療法
ES2823756T3 (es) Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2015112888A1 (en) Apilimod compositions and methods for using same
WO2023035223A1 (zh) 药物组合物及其用途
CN112218639A (zh) 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合组合物和其使用方法
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
US10821114B2 (en) Derivatives of cephalosporin for treating cancer
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
TW202423445A (zh) 英菲格拉替尼在治療胃癌和腺癌中的用途
EP2571358B1 (en) Combination therapy for treating cancer
AU2019344764B2 (en) Quinoline derivative used for treating small cell lung cancer
Pandey et al. Erlotinib: a targeted anticancer drug
JP2024509269A (ja) 脳がんの治療における使用のためのベルバラフェニブ
JP7308145B2 (ja) 固形腫瘍を治療するための医薬組成物
HK40108904A (zh) 用於脑癌治疗的贝伐拉非尼
RU2827402C2 (ru) Фармацевтическая композиция, содержащая пиридинаминное соединение, и ее применение при ros1-положительном немелкоклеточном раке легкого
EP4731792A2 (en) Compositions comprising antineoplastons and methods of treating lung cancer
WO2024263972A2 (en) Compositions comprising antineoplastons and methods of treating uncommon cancers
JP2025512921A (ja) （１９ｒ）－５－クロロ－３－エチル－１６－フルオロ－１０，１９－ジメチル－２０－オキサ－３，４，１０，１１，２３－ペンタアザペンタシクロ［１９．３．１．０２，６．０８，１２．０１３，１８］ペンタコサ－１（２４），２（６），４，８，１１，１３，１５，１７，２１（２５），２２－デカエン－２２－アミンを使用して固形腫瘍の治療する方法
WO2024263801A2 (en) Compositions comprising antineoplastons and methods of treating ovarian cancer
WO2024263966A2 (en) Compositions comprising antineoplastons and methods of treating pancreatic cancer
EP4727534A1 (en) Compositions comprising antineoplastons and methods of treating breast cancer
WO2024263813A2 (en) Compositions comprising antineoplastons and methods of treating colorectal cancer
HK40108632A (zh) 癌的治疗或预防用药物
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241212

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260218

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260317